Live data from Hacker News

Efficacy of hydroxychloroquine in patients with Covid-19: a randomized trial

medrxiv.org

1–10 of 123 posts

Re: Efficacy of hydroxychloroquine in patients with Covid-19: a randomized trial

#5

“ Significance: Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia.”

So hate to ask this, can you explain this for non-medical spectators? Specifically what TTCR and is "absorption of pneumonia" a good thing (e.g. the body has absorbed the pneumonia and therefore it has gone away) or a bad thing (e.g. the body has absorbed the pneumonia and therefore has "collected" more)?

From Paper:

TTCR: Time to clinical recovery

Re: Efficacy of hydroxychloroquine in patients with Covid-19: a randomized trial

#6
The sample size is 62 and the mortality rates are between 0% and 7% depending primarily on age and co-morbidities. I don't think we can draw any meaningful conclusions from this other than what we already know: seems worth looking into HCQ more.

Re: Efficacy of hydroxychloroquine in patients with Covid-19: a randomized trial

#10

So it works?

It looks as if this was better executed than the earlier, criticized study, but with just 2x32 patients, we'll probably have to wait for replication.

One thing that certainly should be cleared up is the age effect: they report "No difference in the age ... distribution ", but that's not enough.

Post reply on HN